⌘K
t
On 23 December 2025, Physiomics plc announced its Board approved an award of 4,548,132 share options to Mr Jesse Thissen, Head of Biometrics, under its existing share option scheme. These options comprise three tranches of 1,516,044 each, with exercise prices of 0.41 pence, 0.79 pence, and 1.29 pence, representing premiums of 41%, 172%, and 345% respectively to the closing mid-market price on 22 December 2025. The options vest over periods commencing from 1 July 2026 and can be exercised within 10 years of the grant date.
| Date | 23 Dec 2025 |
| Time | 07:00:07 |
| Category | Director/PDMR dealings |
| ID | 5646M |
23 December 2025
Physiomics plc
("Physiomics" or the "Company")
Options Award
Physiomics plc (AIM: PYC), announces an award of share options (the "Options") over ordinary shares of 0.4 pence each in the capital of the Company ("Ordinary Shares"). The Company considers that it is important to incentivise its key employees to create shareholder value and, as such, today the Board has approved the award of the following options to Mr Jesse Thissen, Head of Biometrics, under the Company's existing share option scheme (the "Scheme"):
1. 1,516,044 Options with an exercise price of 0.41 pence, representing a 41% premium to the closing mid-market price per Ordinary Share on 22 December 2025. All these Options vest on the first anniversary of Mr Thissen's employment, being 1 July 2026.
2. 1,516,044 Options with exercise price of 0.79 pence, representing a 172% premium to the closing mid-market price per Ordinary Share on 22 December 2025. One third of these Options vest on each anniversary of Mr Thissen's employment (33.3% from 1 July 2026, 66.7% from 1 July 2027 and 100% from 1 July 2028)
3. 1,516,044 Options with an exercise price of 1.29 pence, representing a 345% premium to the closing mid-market price per Ordinary Share on 22 December 2025. These Options vest over the same time periods as described under (2) above.
All Options can be exercised within 10 years of the date of grant.
The total number of options issued to date under the Scheme is 4,548,132.
Dr Peter Sargent, CEO of Physiomics, commented:
"As the Company pursues growth and a transition to cash generation, the establishment of a scalable second service line represents a significant milestone in this strategy. We are pleased to announce that following Jesse's appointment in July 2025, he has played an integral role in launching our new Biometrics service line. Within the first six months, he has secured and commenced delivery on three contracts supporting new therapies for infectious and immunological diseases. Jesse has demonstrated strong leadership in advancing the Biometrics service line and continues to contribute effectively across the broader organisation."
Enquiries:
Physiomics plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494